BioNexus Gene Lab Corp(BGLC)
$0.86+0.04 (+4.63%)
BGLC
BioNexus Gene Lab Corp financials statements
$0.86
At close:+0.04 (+4.63%)
BioNexus Gene Lab Corp (BGLC) Ratios
112 Followers
BioNexus Gene Lab Corp Ratios
BGLC's free cash flow for Q2 2026 was $-443.75K. For the 2026 fiscal year, BGLC's free cash flow was decreased by $-21.26K and operating cash flow was $-422.49K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.46 | 3.81 | 4.93 | 3.00 | 3.04 |
| Quick Ratio | 9.16 | 3.10 | 4.24 | 2.52 | 2.39 |
| Cash Ratio | 4.57 | 2.24 | 3.64 | 1.06 | 0.91 |
| Solvency Ratio | -4.42 | -0.68 | -1.45 | -0.12 | 0.36 |
| Operating Cash Flow Ratio | -3.53 | -1.15 | -1.08 | 0.28 | 0.00 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -133.40 | 33.30 | 0.23 |
| Net Current Asset Value | $ 4.81M | $ 5.32M | $ 6.30M | $ 3.95M | $ 4.69M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.25 | 1.18 | 1.31 | 1.33 |
| Debt Service Coverage Ratio | -143.12 | -67.34 | -92.40 | -8.20 | 16.63 |
| Interest Coverage Ratio | -161.62 | -74.42 | -186.20 | -23.33 | 81.39 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.11 | 0.13 | 0.09 | 0.05 | 0.06 |
| Net Debt to EBITDA | 0.79 | 2.93 | 2.33 | 11.10 | -1.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 14.62% | 13.56% | 13.61% | 11.52% | 16.42% |
| EBIT Margin | -39.93% | -16.55% | -26.54% | -2.66% | 7.90% |
| EBITDA Margin | -37.67% | -14.94% | -25.43% | -1.70% | 8.71% |
| Operating Profit Margin | -42.54% | -16.55% | -26.54% | -2.66% | 7.90% |
| Pretax Profit Margin | -40.20% | -16.77% | -26.69% | -2.78% | 7.80% |
| Net Profit Margin | -40.20% | -16.81% | -26.91% | -3.26% | 5.62% |
| Continuous Operations Profit Margin | -40.20% | -16.81% | -26.91% | -3.26% | 5.62% |
| Net Income Per EBT | 100.00% | 100.22% | 100.83% | 117.23% | 72.07% |
| EBT Per EBIT | 94.50% | 101.34% | 100.54% | 104.29% | 98.77% |
| Return on Assets (ROA) | -32.26% | -15.32% | -23.06% | -4.07% | 7.85% |
| Return on Equity (ROE) | -34.64% | -19.20% | -27.22% | -5.34% | 10.47% |
| Return on Capital Employed (ROCE) | -36.17% | -18.55% | -26.55% | -4.32% | 14.57% |
| Return on Invested Capital (ROIC) | -35.93% | -18.44% | -26.42% | -4.31% | 10.44% |
| Return on Tangible Assets | -32.26% | -15.32% | -23.06% | -4.07% | 7.85% |
| Earnings Yield | -40.70% | -32.04% | -28.80% | -0.22% | 0.21% |
| Efficiency Ratios | |||||
| Receivables Turnover | 11.44 | 6.02 | 11.40 | 3.77 | 3.98 |
| Payables Turnover | 2715.07 | 5.47 | 6.02 | 5.20 | 5.55 |
| Inventory Turnover | 9.37 | 5.92 | 7.42 | 9.89 | 7.34 |
| Fixed Asset Turnover | 4.18 | 5.47 | 5.91 | 6.97 | 7.98 |
| Asset Turnover | 0.80 | 0.91 | 0.86 | 1.25 | 1.40 |
| Working Capital Turnover Ratio | 1.43 | 1.60 | 1.87 | 2.49 | 2.85 |
| Cash Conversion Cycle | 70.73 | 55.55 | 20.59 | 63.51 | 75.67 |
| Days of Sales Outstanding | 31.90 | 60.65 | 32.02 | 96.85 | 91.69 |
| Days of Inventory Outstanding | 38.96 | 61.65 | 49.20 | 36.91 | 49.74 |
| Days of Payables Outstanding | 0.13 | 66.74 | 60.63 | 70.25 | 65.76 |
| Operating Cycle | 70.86 | 122.30 | 81.22 | 133.76 | 141.43 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.99 | -1.25 | -1.02 | 0.38 | 0.01 |
| Free Cash Flow Per Share | -1.01 | -1.38 | -1.11 | 0.35 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | -49.72 | -9.84 | -11.79 | 10.19 | 2.90 |
| Capital Expenditure Coverage Ratio | -49.72 | -9.84 | -11.79 | 10.19 | 2.90 |
| Operating Cash Flow Coverage Ratio | -10.44 | -10.61 | -12.01 | 9.72 | 0.12 |
| Operating Cash Flow to Sales Ratio | -0.25 | -0.23 | -0.18 | 0.05 | 0.00 |
| Free Cash Flow Yield | -25.57% | -49.33% | -20.93% | 0.30% | 0.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.45 | -3.11 | -3.47 | -461.48 | 485.43 |
| Price-to-Sales (P/S) Ratio | 0.99 | 0.52 | 0.93 | 15.03 | 27.30 |
| Price-to-Book (P/B) Ratio | 0.85 | 0.60 | 0.95 | 24.65 | 50.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.91 | -2.03 | -4.78 | 330.09 | 60816.36 |
| Price-to-Operating Cash Flow Ratio | -3.99 | -2.23 | -5.18 | 297.69 | 39825.06 |
| Price-to-Earnings Growth (PEG) Ratio | -0.03 | 0.08 | -0.01 | 3.14 | -8.28 |
| Enterprise Value Multiple | -1.83 | -0.58 | -1.35 | -873.21 | 311.66 |
| Enterprise Value | 5.13M | 822.30K | 3.34M | 162.21M | 362.79M |
| EV to EBITDA | -1.83 | -0.58 | -1.35 | -873.21 | 311.66 |
| EV to Sales | 0.69 | 0.09 | 0.34 | 14.84 | 27.15 |
| EV to Free Cash Flow | -2.73 | -0.33 | -1.75 | 325.95 | 60475.14 |
| EV to Operating Cash Flow | -2.79 | -0.37 | -1.90 | 293.95 | 39601.61 |
| Tangible Book Value Per Share | 4.64 | 4.67 | 5.61 | 4.63 | 5.03 |
| Shareholders’ Equity Per Share | 4.64 | 4.67 | 5.61 | 4.63 | 5.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.01 | -0.17 | 0.28 |
| Revenue Per Share | 4.00 | 5.34 | 5.67 | 7.58 | 9.37 |
| Net Income Per Share | -1.61 | -0.90 | -1.53 | -0.25 | 0.53 |
| Tax Burden | 1.00 | 1.00 | 1.01 | 1.17 | 0.72 |
| Interest Burden | 1.01 | 1.01 | 1.01 | 1.04 | 0.99 |
| Research & Development to Revenue | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| SG&A to Revenue | 0.55 | 0.42 | 0.25 | 0.16 | 0.09 |
| Stock-Based Compensation to Revenue | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.62 | 1.40 | 0.67 | -1.55 | 0.01 |
Currency in USD
